Fundraising Fox

Unleash Immuno Oncolytics

St. Louis, US · Founded 2015 · Delaware corporation

Biotech

Founders & leadership

AM
Ariel MusleraNamed on SEC filing
RL
Ricardo Lisandro BrilNamed on SEC filing
DK
Daniel KatzmanNamed on SEC filing
BC
Bolten CharlesNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$3M disclosed across 1 round · 2018

▶$3MraisedFeb 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ariel MusleraDirector
  • Ricardo Lisandro BrilDirector
  • Daniel KatzmanExecutive Officer, Director
  • Bolten CharlesDirector
Offering amount
$3M
Amount sold
$3M
First sale
Feb 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

TransCode licencia plataforma de terapia contra cáncer de vejiga de Unleash/n Por Investing.comes.investing.com · Mar 2026M&As this week: Oncolys BioPharma, Alira Health, NL-HOLDING - Clinical Trials Arenaclinicaltrialsarena.com · Feb 2018Biotech startup Unleash Immuno Oncolytics raises $3 million to develop the next generation of oncolytic viruses for the treatment of cancer - TechStartupstechstartups.com · Feb 2018

Frequently asked questions

How much funding has Unleash Immuno Oncolytics raised?
Unleash Immuno Oncolytics has disclosed $3M raised across 1 round.
Where is Unleash Immuno Oncolytics headquartered?
Unleash Immuno Oncolytics is headquartered in St. Louis, US.